로딩 중…
StockDiggingStockDigging

코오롱생명과학

102940· KOSDAQ
₩47,850-2.35%
2026-06-19

Price Chart

코오롱생명과학+47.00%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap626.39B KRW
Revenue213.81B KRW
Net Income-9.58B KRW
Total Assets1.15T KRW
Net Assets784.13B KRW
Employees444
Value
P/B0.80x
P/S2.93x
EV/EBITDA4678.84x
FCF Yield-4.48%
Profitability
ROE-1.22%
ROA-0.83%
Op. Margin0.08%
Revenue Growth10.76%
Earnings Growth98.91%
Financial Health
Debt Ratio146.46%
Total Debt218.73B KRW
FCF-28.05B KRW
Cash9.61B KRW
Current Ratio0.73x
Dividend
Div. Growth0.00%
Performance
1Y Return47.00%
1M Return-6.73%
From 52W High-34.18%
1Y MDD-36.86%
Trading
Volume18,488 shares
Foreign Own.5.03%
Per Share
EPS2,799 KRW
BPS59,900 KRW

Company Info

CEO 김선진
Employees 444
Founded 2000
HQ 서울특별시 강서구, KR

Kolon Life Science, established in 2000 and listed on KOSDAQ in 2009, focuses on the production of active pharmaceutical ingredients (APIs), antimicrobial agents, and bio-new drug research and development. Its pharmaceutical business supplies APIs and pharmaceutical intermediates globally, and it markets the eco-friendly antimicrobial brand Cleanbio for use in anti-dandruff shampoos and paints. The company is dedicated to cell and gene new drug development, concentrating on research and development for neuropathic pain treatments and anticancer drugs. Kolon Life Science is headquartered in Gangseo-gu, Seoul Metropolitan City.